To The Moon

$Novo Nordisk(NVO)$ on Sunday said full results from two late-stage trials of its experimental weight-loss drug CagriSema show that side effects were mainly mild-to-moderate and other outcome results,

June 18 - Scholar Rock said on Wednesday its experimental drug helped overweight patients preserve lean mass in a mid-stage trial when used in combination with Eli Lilly's weight-loss treatment Zepbound.Shares of Scholar Rock jumped 13.8% in premarket trading.Scholar's drug, apitegromab, when combined with Zepbound preserved an additional 1.9 kilograms of lean mass when compared with Zepbound alone.Patients who took the drugs in combination also lost more fat mass than those on Zepbound alone.E